Generic, Brand-Name Medication Similarly Effective for COPD
08 Aug 2023
Clinical Result
MONDAY, Aug. 7, 2023 -- For patients with chronic obstructive pulmonary disease (COPD), generic and brand-name fluticasone-salmeterol are similarly effective and safe, according to a study published online Aug. 8 in the Annals of Internal Medicine.
William B. Feldman, M.D., D.Phil., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of generic (Wixela Inhub) and brand-name (Advair Diskus) fluticasone-salmeterol among patients with COPD in a propensity score-matched cohort study. Of 27,305 Advair Diskus users and 18,064 Wixela Inhub users, 10,012 matched pairs were included in the primary analysis.
The researchers found that Wixela Inhub use was associated with a nearly identical incidence of first moderate or severe COPD exacerbation compared with Advair Diskus (hazard ratio, 0.97; 95 percent confidence interval, 0.90 to 1.04) and with a similar incidence of first pneumonia hospitalization (hazard ratio, 0.99; 95 percent confidence interval, 0.86 to 1.15).
"In patients with COPD, the generic inhaled corticosteroid-long-acting β-agonist Wixela Inhub had nearly identical effectiveness and safety when compared with brand-name Advair Diskus," the authors write. "Similar studies can provide a useful means of evaluating the clinical effectiveness and safety of complex generic products after approval."
Abstract/Full Text (subscription or payment may be required)
Posted August 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.